Black Diamond Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Black Diamond Therapeutics

01/08/2025 14:45

Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 25 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 89.5% in the last three months. ​

Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.8% above its last closing price of $2.66

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.49
0.02
0.98
Beat
4,511.8
Dec. 31 2025
-0.31
-0.28
Beat
11
Sep. 30 2024
-0.38
-0.37
-0.28
Beat
25.1​
Jun. 30 2024
-0.38
-0.39
-0.36
Beat
7
​​Mar. 31 2024
-0.42
-0.43
-0.35
Beat
19.5
Dec. 31 2023
-0.45
-0.47
-0.34
Beat
27​
Sep. 30 2023
-0.44
-0.49
-0.45
Beat
7.5
Jun. 30 2023
-0.54
-0.54
-0.52
Beat
3

This summary was machine generated August 1 at 13:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)